Overview and recent developments in the medical management of paediatric uveitis

Bibliography

• Jabs D, Nussenblatt R, Rosenbaum J; SoUNSW Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16
   PubMed Web of Science ®Google Scholar
• Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Experiment Ophthalmol 2001;29(2):81-4
   Google Scholar
• Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol 2003;135:867-78
   PubMed Web of Science ®Google Scholar
• Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 2003;135:676-80
   PubMed Web of Science ®Google Scholar
• Cunningham ET. Uveitis in children. Ocul Immunol Inflamm 2000;8:251-61
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I. Pediatric uveitis. J Ophthalmic Vis Res 2011;6:259-69
   PubMedGoogle Scholar
• Pivetti-Pezzi P. Uveitis in children. Eur J Ophthalmol 1996;6:293-8
   PubMedGoogle Scholar
• deBoer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003;87:879-84
   Google Scholar
• Jain R, Ferrante P, Reddy GT, Lightman S. Clinical features and visual outcome of intermediate uveitis in children. Clin Exp Ophthalmol 2005;33(1):22-5
   PubMedGoogle Scholar
• Azar D, Martin F. Paediatric uveitis: a Sydney clinic experience. Clin Exp Ophthalmol 2004;32:468-71
   PubMed Web of Science ®Google Scholar
• Latkany PA, Jabs DA, Smith JR, et al. Multifocal choroiditis in patients with familial juvenile granulomatosis. Am J Ophthalmol 2002;134:897-903
   PubMedGoogle Scholar
• Burns JC, Joffe L, Sargent RA, Glode MP. Anterior uveitis associted with Kawasaki's syndrome. Paediatr Infect Dis 1985;4:258-61
   PubMedGoogle Scholar
• Paroli MP, Spinucci G, Liverani M, et al. Uveitis in childhood: an Italian clinical and epidemiological study. Ocul Immunol Inflamm 2009;17:238-42
   PubMed Web of Science ®Google Scholar
• Kump LI, Cervantes-Castaneda RA, Androudi SN, et al. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006;113:1874-7
   PubMed Web of Science ®Google Scholar
• Gregory AC II, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 2013;120(1):186-92
   Google Scholar
• BenEzra D, Cohen E. Cataract surgery in children with chronic uveitis. Ophthalmology 2000;107:1255-60
   PubMed Web of Science ®Google Scholar
• Lyon F, Gale RP, Lightman S. Recent developments in the treatment of uveitis: an update. Expert Opin Investig Drugs 2009;18:609-16
   PubMed Web of Science ®Google Scholar
• Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002;29:1296-300
   PubMed Web of Science ®Google Scholar
• Comstock TL, DeCory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflammation 2012;2012:1-11
   Google Scholar
• Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010;9:674-83
   PubMed Web of Science ®Google Scholar
• Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic uveitis treated with topical corticosteroids. Ophthalmology 2010;117:1436-41
   PubMed Web of Science ®Google Scholar
• Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol 2009;3:381-90
   PubMedGoogle Scholar
• Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol 2012;153(5):932-8
   PubMed Web of Science ®Google Scholar
• Habot-Wilner Z, Sallam A, Roufas A, et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol 2010;88:299-304
   PubMedGoogle Scholar
• Inoue M, Takeda K, Morita K, et al. Vitreous concentrations of triamcinolone acetonide in human eyes after vitreal or subtenon injection. Am J Ophthalmol 2004;138(6):1046-8
   PubMed Web of Science ®Google Scholar
• Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008;126:200-5
   PubMed Web of Science ®Google Scholar
• Roth DB, Flynn HW Jr. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 2008;146:346-7
   PubMed Web of Science ®Google Scholar
• Lobo AM. Dexamethasone intravitreal implant for the treatment of non-infectious uveitis. Clin Ophthalmol 2011;5:1613-21
   Google Scholar
• Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53
   PubMed Web of Science ®Google Scholar
• Taylor SR, Tomkins-Netzer O, Joshi L, et al. Dexamethasone implant in pediatric uveitis. Ophthalmology 2012;119:2412
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-201
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916-26
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012;32:1121-33
   PubMed Web of Science ®Google Scholar
• Cantarini L, Simonini G, Frediani B, et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Invest Drugs 2012;21(1):1-6
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108:1134-9
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-19
   PubMed Web of Science ®Google Scholar
• Kalina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011;15(2):217-22
   Google Scholar
• Payne K, Newman W, Fargher E, et al. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology 2007;46:727-9
   PubMed Web of Science ®Google Scholar
• Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment priot to starting thiopurine drug treatment ; a pharmacogenetic test whose time has come. J Clin Pathol 2010;63:288-95
   PubMed Web of Science ®Google Scholar
• Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol 2011;95:209-13
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007;91:180-4
   PubMed Web of Science ®Google Scholar
• Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye 2011;25:427-35
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998;82:737-42
   PubMed Web of Science ®Google Scholar
• Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 1998;105:2028-34
   PubMed Web of Science ®Google Scholar
• Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010;58:55-8
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 2009;23:1192-8
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-41
   PubMed Web of Science ®Google Scholar
• Roesel M, Tappeiner C, Heiligenhaus A, Heinz C. Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis. Clin Ophthalmol 2011;5:1309-13
   Google Scholar
• Mirshahi A, Hoehn R, Lorenz K, et al. Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res 2012;7:39-44
   PubMedGoogle Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs 2011;16:309-22
   PubMed Web of Science ®Google Scholar
• Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2010;50:189-95
   Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumour necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56(10):3248-52
   PubMed Web of Science ®Google Scholar
• SYCAMORE TRIAL. Available from: http://www.sycamoretrial.org.uk [Accessed 10 March 2013]
   Google Scholar
• Saurenmann R K, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006;45:982-9
   Google Scholar
• Foeldvari I, Nielesen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2006;66:548-50
   PubMed Web of Science ®Google Scholar
• Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye 2009;23:1868-70
   PubMed Web of Science ®Google Scholar
• Manadan AM, Block JA. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am J Ther 2008;15:53-8
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011;50:1390-4
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
   PubMedGoogle Scholar